表观遗传生物标志物在人类疾病早期诊断与治疗中的研究进展
Research progress of epigenetic biomarkers in the early diagnosis and treatment of human diseases.
作者信息
Li Wei, Qin Jun, Wang Hui, Chen Liao-Bin
机构信息
Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan 430071, China;Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China.
出版信息
Yi Chuan. 2018 Feb 20;40(2):104-115. doi: 10.16288/j.yczz.17-220.
Abnormal epigenetic modifications are common in many diseases (such as tumors, senile and developmental diseases), and can influence the pathogenesis and progression of these diseases. Various studies demonstrated that abnormal epigenetic changes could be used as biomarkers for diagnosis of the disease status and prognosis of disease progression. The reversibility and controllability of epigenetic modifications also offer an opportunity to develop new strategies for the early prevention and treatment of diseases. In this review, we provide a brief overview of the latest discoveries in three areas of epigenetic research, i.e., DNA methylation, histone modifications and non-coding RNAs, and their potential applications in early diagnosis and treatment of tumors, senile and developmental diseases. We hope to provide some insights and references in developing strategies for the diagnosis and treatment of these diseases.
异常的表观遗传修饰在许多疾病（如肿瘤、衰老和发育性疾病）中很常见，并可影响这些疾病的发病机制和进展。各种研究表明，异常的表观遗传变化可作为疾病状态诊断和疾病进展预后的生物标志物。表观遗传修饰的可逆性和可控性也为开发疾病早期预防和治疗的新策略提供了机会。在这篇综述中，我们简要概述了表观遗传学研究三个领域的最新发现，即DNA甲基化、组蛋白修饰和非编码RNA，以及它们在肿瘤、衰老和发育性疾病早期诊断和治疗中的潜在应用。我们希望为制定这些疾病的诊断和治疗策略提供一些见解和参考。
Zotero 插件